ViiV caboegravir announcement: Governments must intervene, campaigners say

Responding to ViiV’s announcement that it will triple annual supply of long-acting HIV PrEP for low- and middle-income countries, Dr Mohga Kamal-Yanni, Policy co-lead for the People’s Medicines Alliance, said:

“Increasing production of long-acting cabotegravir is a start, but, ViiV has consistently excluded many low and middle-income countries from licenses for inexpensive generic versions of its medicines. Moreover, the company has launched a legal challenge to prevent Colombia from accessing a generic version of a first line HIV medicine, dolutegravir. 

“Enough is enough. We cannot keep waiting for pharmaceutical companies to do the right thing on their own terms. Governments must intervene to ensure that affordable medicines are available for their people.”

/Ends

Notes

This is a response to an announcement from British pharmaceutical company ViiV: https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2024/october/triple-annual-supply-of-long-acting-hiv-prep-for-low-and-middle-income-countries/

Media contact

Joe Karp-Sawey
[email protected]